Real-World Evidence Studies Find Remdesivir Effective for Immunocompromised Patients with COVID-19

April 17, 2023

Gilead Sciences, manufacturers of Remdesivir, announced results from 2 real-world evidence (RWE) studies demonstrating the efficacy and safety of the drug in immunocompromised patients with COVID-19. The first study showed that the anti-viral medication reduced mortality significantly in patients living with cancer and all previous variants of COVID-19.

According to Gilead, “In the second analysis, 4,664 immunocompromised patients were evaluated and those who received treatment with Veklury (n=2,332) had lower risk for hospital readmission at both 30- and 60-day time periods. Results demonstrated that 60-day readmission rates were 16% lower for patients treated with Veklury during the Delta wave (HR:0.84, 95% CI:0.71-0.96; p<0.01) and 13% lower during the Omicron wave (HR:0.87, 95% CI:0.81-0.93; p<0.01) compared to matched controls (n=2,332). These data further confirm RWE presented at CROI earlier this year which demonstrated that use of Veklury was associated with a reduced risk of 30-day all-cause readmission.”

To read more, click here.